Because it is a test for healthy subjects, there is no target disease.
Conditions
Interventions
Dry mozuku powder blending sprinkle
Dry mozuku powder non-blended sprinkle
Sponsors
Wellbe Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy people who do not have severe disease 2. A person who wishes voluntarily to participate in clinical trials in men and women aged 20 years or over and under 65 years old and who can obtain written informed consent 3.Those who can withdraw laxatives, constipation drugs, supplements expected to have bowel improvement effect, health tea etc during the examination period. 4. people with constipation tendency (stool frequency ~ 3 times / week, excluding severe constipation) 5. Those who do not take supplements that are predicted to constantly improve constipation medicine and bowel movement within the first month 6. Who can keep daily lifestyle habits constant during the examination period 7. Study participation of people who are treating mild chronic diseases (hypertension, hyperlipemia, etc.) shall be able to participate at the discretion of the investigator
Exclusion criteria
Exclusion criteria: 1. People with severe diseases (heart disease, liver disease, kidney disease, cancer, etc.) and mental illness. 2. People with digestive system disease history and surgery history of digestive organs. 3. constipation who may be caused by diseases (colorectal cancer, Crohn's disease, etc.) and drugs (anticholinergics, antidepressants, etc.) 4. Those who can not maintain everyday life habits with large changes in diet and exercise. 5. If you work on shifts, work at midnight.] 6. Persons who constantly take on laxatives, constipation medicine and supplements, health tea etc. expected to improve bowel movement regularly or within 1 month of the month within 1 month. 7. Possible food allergy and drug allergy to the test food. 8. Pregnant women / lactating women and those who wish pregnant during the examination period. 9. Others who have made the examination responsible doctor ineligible for participation in this exam. 10. Those who participate in other clinical trials within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ratio of Bifidobacterium to the number of intestinal inner layer bacteria | — |
Secondary
| Measure | Time frame |
|---|---|
| Defecation status | — |
Countries
Japan
Contacts
Public ContactAbe, Hiroyuki
Wellbe Inc. Clinical Research Division
Outcome results
None listed